Objective: To explore the clinical characteristics, treatment and prognosis of therapy-related hematological neoplasms patients secondary to malignant solid tumors.
Methods: The clinical features, treatment and prognosis of 36 hematological neoplasms patients secondary to malignant solid tumors with radiotherapy and chemotherapy in the Second Hospital of Shanxi Medical University were retrospectively analyzed.
Results: The 36 patients with therapy-related hematological neoplasms had a median age of 60 (47-81) years, 14 were male and 22 were female. Among them, 22 cases were acute myeloid leukemia, 5 cases were acute lymphoblastic leukemia, 4 cases were multiple myeloma, 3 cases were myelodysplastic syndrome, and 2 cases were non-hodgkin's lymphoma. The median latency of malignant tumor to hematological neoplasm was 42.5 (12-120) months. The median survival time of therapy-related hematological neoplasms was 10.5 (1-83) months, and the 3-year overall survival (OS) rate was 24.3%. The therapy-related acute myeloid leukemia patients had a very poor prognosis, with a median survival of 7 (1-83) months and a 3-year OS rate of 21.4%.
Conclusion: The prognosis of therapy-related hematological neoplasms secondary to malignant solid tumors with radiotherapy and chemotherapy is poor, and individualized treatment should be implemented according to the clinical situation of patients.
题目: 恶性实体瘤放化疗后继发血液肿瘤患者临床及预后分析.
目的: 探讨恶性实体瘤治疗相关血液肿瘤患者的临床特点、治疗及预后.
方法: 对山西医科大学第二医院收治的恶性实体瘤放化疗后继发血液肿瘤36例患者的临床特征、治疗及预后进行回顾性分析.
结果: 36例治疗相关血液肿瘤患者中位年龄60（47-81）岁，男性14例，女性22例；急性髓系白血病22例，急性淋巴细胞白血病5例，多发性骨髓瘤4例，骨髓增生异常综合征3例，非霍奇金淋巴瘤2例。恶性实体瘤至血液肿瘤发生的中位潜伏期为42.5（12-120）个月。治疗相关血液肿瘤中位生存时间为10.5（1-83）个月，3年总生存（OS）率为24.3%，治疗相关急性髓系白血病中位生存时间为7（1-83）个月，3年OS率为21.4.
结论: 恶性实体瘤患者放化疗后其远期并发症治疗相关血液肿瘤预后差，需根据患者临床情况实施个体化治疗.
Keywords: chemotherapy; hematological neoplasms; malignant tumors; radiotherapy.